🔗 Share this article

Government ministers and leading parliamentarians have issued warnings that the United Kingdom's negotiated accords with the US administration are "lacking a solid foundation." This comes after revelations that a recently announced deal on drug pricing, which promises zero tariffs in exchange for the NHS paying more, lacks any underlying contract beyond vague headline terms published in government press releases.

A Deal Without Detail

The deal on drug tariffs, promoted as a "generational" achievement, is still an "broad understanding" without a signed legal text. It has been highlighted that the official announcements from the UK and US governments frame the deal in markedly contrasting terms. The British version focuses on securing "zero per cent tariffs" as a unique achievement, while the American announcement dwells on the expectation for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has promised concessions to increase medicine costs in return for only a assurance from President Trump," said David Henig, a trade policy analyst. "We know he has a record of not honouring his word."

Broader Instability and a Paused Tech Deal

Worries have been intensified by Washington's recent decision to put on ice the high-value digital accord, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US pointed to a lack of progress from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions promised for British farmers as part of an May trade agreement have not been formally signed off by the US, despite a looming January deadline. "We have been informed that that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Privately, ministers have voiced worries that the government's agreements with the US are unstable and unpredictable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another characterized the situation as the "prevailing condition" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, remarked: "The only thing more surprising than Trump's temper tantrums is the UK government's credulous faith that his administration is a good faith actor. The NHS is not a bargaining chip."

A Mixed Picture of Success and Setback

Officials have sought to reduce the chances of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials concede that unpredictability is a feature of dealing with the current US leadership. However, they contend that the UK has achieved real benefits for businesses, such as preferential tariff rates compared to other nations. "Securing 25% steel tariffs, which is more favorable than the rate for the rest of the world, is not flimsy," one official said.

Nevertheless, problems have emerged in carrying out the broader trade deal. Promised access for British beef have not materialized, and the assurance to "reduce steel tariffs to zero" has is still pending, with tariffs remaining at 25%.

As negotiations continue, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.